Articles from Tolerance Bio, Inc.

Tolerance Bio, Inc. (“Tolerance Bio” or the “Company”), a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, today announced an exclusive license agreement with NeoImmuneTech (NIT, KOSDAQ: 950220.KQ) for the development and commercialization of efineptakin alfa (also known as NT-I7), a clinical-stage long-acting IL-7 fusion protein, for certain thymus-related indications in the Americas and Europe.

Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the publication of a scientific article titled “Patient-specific autologous thymic organoids support functional T-cell education leading to antitumor activity in humanized mice with melanoma xenografts” in Cancer Research Communications, a journal of the American Association for Cancer Research. The research was led by Antonio Jimeno, M.D., Ph.D., from the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine, and Holger A. Russ, Ph.D., from the Diabetes Institute and the Department of Pharmacology and Therapeutics, College of Medicine at the University of Florida, Gainesville, and scientific co-founder of Tolerance Bio.

Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and ZipCode Bio, a biotechnology company developing next-generation RNA medicines, today announced a strategic research and development collaboration aimed at pioneering novel delivery methods for targeted thymus therapeutics.

Tolerance Bio, Inc., a biopharmaceutical company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2 million seed financing round.

Tolerance Bio, Inc., a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners and individual biotechnology investors.